Literature DB >> 22314683

Expression of equilibrative nucleoside transporter type 1 protein in elderly patients with schizophrenia.

Dan Shan1, Vahram Haroutunian, James H Meador-Woodruff, Robert E McCullumsmith.   

Abstract

Alterations in glutamatergic neurotransmission are thought to be involved in several psychiatric disorders, including schizophrenia. Equilibrative nucleoside transporter type 1 (ENT1) regulates glutamate levels by regulating excitatory amino acid transporter expression and activity in the brain. In this study, we investigated whether ENT1 is abnormally expressed in the brain of elderly patients with schizophrenia. We measured protein expression of ENT1 in the superior temporal gyrus (STG) and anterior cingulate cortex (ACC) in patients with schizophrenia (STG, n=22; ACC, n=34) and a comparison group (STG, n=24; ACC, n=29). We found decreased ENT1 expression in the STG in patients with schizophrenia, supporting the hypothesis of altered glutamate transport in this illness.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22314683      PMCID: PMC3685430          DOI: 10.1097/WNR.0b013e3283500987

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  19 in total

1.  ENT1 regulates ethanol-sensitive EAAT2 expression and function in astrocytes.

Authors:  Jinhua Wu; Moonnoh R Lee; Sun Choi; Taehyun Kim; Doo-Sup Choi
Journal:  Alcohol Clin Exp Res       Date:  2010-04-05       Impact factor: 3.455

2.  Expression of the NR2B-NMDA receptor trafficking complex in prefrontal cortex from a group of elderly patients with schizophrenia.

Authors:  L V Kristiansen; B Bakir; V Haroutunian; J H Meador-Woodruff
Journal:  Schizophr Res       Date:  2010-03-29       Impact factor: 4.939

3.  Variations in differential gene expression patterns across multiple brain regions in schizophrenia.

Authors:  P Katsel; K L Davis; J M Gorman; V Haroutunian
Journal:  Schizophr Res       Date:  2005-09-15       Impact factor: 4.939

4.  Presynaptic regulation of quantal size by the vesicular glutamate transporter VGLUT1.

Authors:  Nathan R Wilson; Jiansheng Kang; Emily V Hueske; Tony Leung; Helene Varoqui; Jonathan G Murnick; Jeffrey D Erickson; Guosong Liu
Journal:  J Neurosci       Date:  2005-06-29       Impact factor: 6.167

Review 5.  Adenosine and its receptors: multiple modulatory functions and potential therapeutic targets for neurologic disease.

Authors:  Eduardo E Benarroch
Journal:  Neurology       Date:  2008-01-15       Impact factor: 9.910

6.  The type 1 equilibrative nucleoside transporter regulates anxiety-like behavior in mice.

Authors:  J Chen; L Rinaldo; S-J Lim; H Young; R O Messing; D-S Choi
Journal:  Genes Brain Behav       Date:  2007-03-21       Impact factor: 3.449

7.  Evidence for abnormal forward trafficking of AMPA receptors in frontal cortex of elderly patients with schizophrenia.

Authors:  John C Hammond; Robert E McCullumsmith; Adam J Funk; Vahram Haroutunian; James H Meador-Woodruff
Journal:  Neuropsychopharmacology       Date:  2010-06-23       Impact factor: 7.853

8.  Altered vesicular glutamate transporter expression in the anterior cingulate cortex in schizophrenia.

Authors:  Akin Oni-Orisan; Lars V Kristiansen; Vahram Haroutunian; James H Meador-Woodruff; Robert E McCullumsmith
Journal:  Biol Psychiatry       Date:  2007-12-26       Impact factor: 13.382

9.  Expression of excitatory amino acid transporter interacting protein transcripts in the thalamus in schizophrenia.

Authors:  Ibone Huerta; Robert E McCullumsmith; Vahram Haroutunian; José Manuel Giménez-Amaya; James H Meador-Woodruff
Journal:  Synapse       Date:  2006-06-01       Impact factor: 2.562

10.  Expression of four housekeeping proteins in elderly patients with schizophrenia.

Authors:  Deborah Elaine Bauer; Vahram Haroutunian; Robert E McCullumsmith; James H Meador-Woodruff
Journal:  J Neural Transm (Vienna)       Date:  2009-01-13       Impact factor: 3.575

View more
  7 in total

1.  Abnormal partitioning of hexokinase 1 suggests disruption of a glutamate transport protein complex in schizophrenia.

Authors:  Dan Shan; Daniel Mount; Stephen Moore; Vahram Haroutunian; James H Meador-Woodruff; Robert E McCullumsmith
Journal:  Schizophr Res       Date:  2014-02-21       Impact factor: 4.939

2.  Deletion of adenosine A2A receptors from astrocytes disrupts glutamate homeostasis leading to psychomotor and cognitive impairment: relevance to schizophrenia.

Authors:  Marco Matos; Hai-Ying Shen; Elisabete Augusto; Yumei Wang; Catherine J Wei; Yu Tian Wang; Paula Agostinho; Detlev Boison; Rodrigo A Cunha; Jiang-Fan Chen
Journal:  Biol Psychiatry       Date:  2015-02-27       Impact factor: 13.382

3.  Update on the neurobiology of schizophrenia: a role for extracellular microdomains.

Authors:  D Shan; S Yates; R C Roberts; R E McCullumsmith
Journal:  Minerva Psichiatr       Date:  2012-09-01

4.  Cell-specific abnormalities of glutamate transporters in schizophrenia: sick astrocytes and compensating relay neurons?

Authors:  R E McCullumsmith; S M O'Donovan; J B Drummond; F S Benesh; M Simmons; R Roberts; T Lauriat; V Haroutunian; J H Meador-Woodruff
Journal:  Mol Psychiatry       Date:  2015-09-29       Impact factor: 15.992

5.  Cell-subtype-specific changes in adenosine pathways in schizophrenia.

Authors:  Sinead Marie O'Donovan; Courtney Sullivan; Rachael Koene; Emily Devine; Kathryn Hasselfeld; Cassidy Lynn Moody; Robert Erne McCullumsmith
Journal:  Neuropsychopharmacology       Date:  2018-02-26       Impact factor: 7.853

6.  Decreased Equilibrative Nucleoside Transporter 1 (ENT1) Activity Contributes to the High Extracellular Adenosine Levels in Mesenchymal Glioblastoma Stem-Like Cells.

Authors:  Sebastián Alarcón; María de Los Ángeles Toro; Carolina Villarreal; Rómulo Melo; Rodrigo Fernández; Angel Ayuso Sacido; Daniel Uribe; Rody San Martín; Claudia Quezada
Journal:  Cells       Date:  2020-08-18       Impact factor: 6.600

Review 7.  Adenosine, Schizophrenia and Cancer: Does the Purinergic System Offer a Pathway to Treatment?

Authors:  Abdul-Rizaq Hamoud; Karen Bach; Ojal Kakrecha; Nicholas Henkel; Xiaojun Wu; Robert E McCullumsmith; Sinead M O'Donovan
Journal:  Int J Mol Sci       Date:  2022-10-05       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.